Hellman Jordan Management Co. Inc. MA purchased a new position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $6,260,000. Regeneron Pharmaceuticals makes up 8.5% of Hellman Jordan Management Co. Inc. MA’s investment portfolio, making the stock its largest holding.
A number of other institutional investors have also recently made changes to their positions in the stock. Altfest L J & Co. Inc. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $538,000. Bank of Nova Scotia raised its position in Regeneron Pharmaceuticals by 25.4% in the 2nd quarter. Bank of Nova Scotia now owns 21,832 shares of the biopharmaceutical company’s stock worth $6,833,000 after buying an additional 4,420 shares during the last quarter. KBC Group NV raised its position in Regeneron Pharmaceuticals by 25.6% in the 2nd quarter. KBC Group NV now owns 48,628 shares of the biopharmaceutical company’s stock worth $15,221,000 after buying an additional 9,912 shares during the last quarter. Calamos Advisors LLC raised its position in Regeneron Pharmaceuticals by 2.1% in the 2nd quarter. Calamos Advisors LLC now owns 11,911 shares of the biopharmaceutical company’s stock worth $3,728,000 after buying an additional 248 shares during the last quarter. Finally, Gargoyle Investment Advisor L.L.C. raised its position in Regeneron Pharmaceuticals by 6.8% in the 2nd quarter. Gargoyle Investment Advisor L.L.C. now owns 1,526 shares of the biopharmaceutical company’s stock worth $478,000 after buying an additional 97 shares during the last quarter. Institutional investors own 66.54% of the company’s stock.
A number of equities analysts have weighed in on REGN shares. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals to $344.00 and set a “market perform” rating for the company in a research report on Wednesday, August 7th. Robert W. Baird raised shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 price target for the company in a research report on Wednesday, August 7th. TheStreet lowered shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Wednesday, June 5th. BidaskClub lowered shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 28th. Finally, Guggenheim raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the company from $355.00 to $403.00 in a research report on Monday, September 23rd. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals has an average rating of “Hold” and an average target price of $396.88.
Shares of NASDAQ REGN traded up $5.25 during midday trading on Monday, hitting $278.71. 22,038 shares of the company’s stock traded hands, compared to its average volume of 653,114. Regeneron Pharmaceuticals Inc has a 1 year low of $271.37 and a 1 year high of $442.00. The stock has a market capitalization of $30.90 billion, a price-to-earnings ratio of 14.09, a price-to-earnings-growth ratio of 1.28 and a beta of 1.13. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.11 and a current ratio of 3.88. The firm has a fifty day moving average of $290.75 and a 200 day moving average of $324.31.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.60 by $0.69. The company had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.80 billion. Regeneron Pharmaceuticals had a return on equity of 25.79% and a net margin of 28.59%. The firm’s revenue was up 20.3% on a year-over-year basis. During the same period in the previous year, the company posted $5.45 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.22 earnings per share for the current year.
In related news, major shareholder Sanofi sold 172,904 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total transaction of $48,611,959.60. Insiders own 11.84% of the company’s stock.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: What is the Stochastic Momentum Index (SMI)?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.